Related Experiment Video
Updated: Feb 28, 2026

06:10
Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
Published on: May 9, 2025
1.0K
Reprogramming CAR T-Cells with designed bioPROTACs
Vivek S Peche1, Sebastian Kenny2,3, Tae Gun Kang4
1Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Biorxiv : the Preprint Server for Biology
|February 27, 2026
Summary
New bioPROTACs offer a reversible, non-gene editing method to enhance CAR T-cell function. This approach targets T-cell exhaustion regulators, providing a tunable strategy for next-generation cell therapies.
Area of Science:
- Immunology
- Molecular Biology
- Biotechnology
Background:
- Gene editing enhances CAR T-cell function by disrupting negative regulators.
- Existing gene editing methods have limitations for therapeutic applications.
Purpose of the Study:
- To explore de novo-designed targeted degraders (bioPROTACs) as an alternative to gene editing for CAR T-cell enhancement.
- To investigate the efficacy of bioPROTACs in targeting DNMT3A, a regulator of T-cell exhaustion.
Main Methods:
- Designed and generated bioPROTACs for CAR T-cell applications.
- Expressed bioPROTACs in CAR T-cells targeting DNMT3A.
- Evaluated the functional effects of bioPROTAC expression on T-cell phenotype.
Main Results:
- BioPROTAC expression in CAR T-cells targeting DNMT3A phenocopied gene knockout effects.
- The bioPROTAC approach demonstrated a reversible and tunable strategy.
- This method successfully reprogrammed T-cell fate, addressing T-cell exhaustion.
Conclusions:
- De novo-designed bioPROTACs provide a viable, non-gene editing alternative for enhancing CAR T-cell function.
- This reversible approach offers tunable control over T-cell fate reprogramming.
- BioPROTACs hold broad applicability for developing next-generation cell therapies.

